David Westenberg
Stock Analyst at Piper Sandler
(4.29)
# 1,309
Out of 4,345 analysts
492
Total ratings
47.9%
Success rate
8.7%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics | Maintained: Buy | $8.5 | $3.93 | +116.28% | 20 | May 12, 2026 | |
| NTRA Natera | Reiterated: Buy | $240 → $249 | $203.11 | +22.59% | 48 | May 12, 2026 | |
| GH Guardant Health | Reiterated: Buy | $130 → $135 | $127.51 | +5.87% | 36 | May 12, 2026 | |
| ADPT Adaptive Biotechnologies | Maintained: Buy | $20 | $13.88 | +44.09% | 35 | May 12, 2026 | |
| TEM Tempus AI | Maintained: Hold | $58 | $47.17 | +22.96% | 14 | May 12, 2026 | |
| CAI Caris Life Sciences | Maintained: Hold | $21 | $15.38 | +36.54% | 3 | May 12, 2026 | |
| PACB Pacific Biosciences of California | Reiterated: Hold | $2 | $1.29 | +55.04% | 29 | May 8, 2026 | |
| TXG 10x Genomics | Maintained: Hold | $19 → $20 | $25.53 | -21.65% | 7 | May 8, 2026 | |
| CTKB Cytek Biosciences | Maintained: Buy | $7.5 | $3.97 | +89.16% | 37 | May 8, 2026 | |
| BLLN BillionToOne | Maintained: Buy | $150 → $130 | $91.02 | +42.83% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $54 → $56 | $71.42 | -21.59% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $30 → $15 | $17.90 | -16.20% | 19 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $130 | $48.21 | +169.65% | 12 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $170 | $150.17 | +13.21% | 51 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $21.73 | +107.09% | 8 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $9.57 | +35.84% | 23 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $270 → $300 | $258.25 | +16.17% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $775 → $750 | $550.99 | +36.12% | 27 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $190 → $135 | $79.48 | +69.85% | 26 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $24 → $30 | $23.69 | +26.64% | 24 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6.5 → $10 | $9.20 | +8.70% | 23 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $190 → $200 | $193.99 | +3.10% | 12 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 150p → 190p | $136.60 | +39.09% | 6 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3.5 → $3 | $6.41 | n/a | 10 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $1.20 | n/a | 1 | Oct 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $32.89 | n/a | 1 | May 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $65 | $113.17 | n/a | 2 | Dec 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $2.17 | n/a | 1 | Jun 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $305.29 | n/a | 2 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $52 | $12.34 | n/a | 1 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $47 | $39.44 | n/a | 1 | Dec 7, 2017 |
Myriad Genetics
May 12, 2026
Maintained: Buy
Price Target: $8.5
Current: $3.93
Upside: +116.28%
Natera
May 12, 2026
Reiterated: Buy
Price Target: $240 → $249
Current: $203.11
Upside: +22.59%
Guardant Health
May 12, 2026
Reiterated: Buy
Price Target: $130 → $135
Current: $127.51
Upside: +5.87%
Adaptive Biotechnologies
May 12, 2026
Maintained: Buy
Price Target: $20
Current: $13.88
Upside: +44.09%
Tempus AI
May 12, 2026
Maintained: Hold
Price Target: $58
Current: $47.17
Upside: +22.96%
Caris Life Sciences
May 12, 2026
Maintained: Hold
Price Target: $21
Current: $15.38
Upside: +36.54%
Pacific Biosciences of California
May 8, 2026
Reiterated: Hold
Price Target: $2
Current: $1.29
Upside: +55.04%
10x Genomics
May 8, 2026
Maintained: Hold
Price Target: $19 → $20
Current: $25.53
Upside: -21.65%
Cytek Biosciences
May 8, 2026
Maintained: Buy
Price Target: $7.5
Current: $3.97
Upside: +89.16%
BillionToOne
May 7, 2026
Maintained: Buy
Price Target: $150 → $130
Current: $91.02
Upside: +42.83%
May 6, 2026
Maintained: Hold
Price Target: $54 → $56
Current: $71.42
Upside: -21.59%
May 5, 2026
Reiterated: Hold
Price Target: $30 → $15
Current: $17.90
Upside: -16.20%
May 5, 2026
Maintained: Buy
Price Target: $130
Current: $48.21
Upside: +169.65%
May 1, 2026
Maintained: Buy
Price Target: $170
Current: $150.17
Upside: +13.21%
May 1, 2026
Maintained: Buy
Price Target: $45
Current: $21.73
Upside: +107.09%
Apr 30, 2026
Reiterated: Buy
Price Target: $13
Current: $9.57
Upside: +35.84%
Feb 24, 2026
Reiterated: Hold
Price Target: $270 → $300
Current: $258.25
Upside: +16.17%
Feb 9, 2026
Maintained: Hold
Price Target: $775 → $750
Current: $550.99
Upside: +36.12%
Jan 22, 2026
Downgraded: Hold
Price Target: $190 → $135
Current: $79.48
Upside: +69.85%
Jan 22, 2026
Upgraded: Buy
Price Target: $24 → $30
Current: $23.69
Upside: +26.64%
Jan 12, 2026
Maintained: Hold
Price Target: $6.5 → $10
Current: $9.20
Upside: +8.70%
Oct 27, 2025
Reiterated: Hold
Price Target: $190 → $200
Current: $193.99
Upside: +3.10%
Sep 3, 2025
Maintained: Buy
Price Target: 150p → 190p
Current: $136.60
Upside: +39.09%
Nov 13, 2023
Rated: Hold
Price Target: $3.5 → $3
Current: $6.41
Upside: n/a
Oct 4, 2021
Initiated Coverage: Buy
Price Target: $28
Current: $1.20
Upside: n/a
May 23, 2019
Initiated Coverage: Hold
Price Target: n/a
Current: $32.89
Upside: n/a
Dec 17, 2018
Upgraded: Buy
Price Target: $65
Current: $113.17
Upside: n/a
Jun 15, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $2.17
Upside: n/a
Feb 16, 2018
Downgraded: Hold
Price Target: n/a
Current: $305.29
Upside: n/a
Jan 4, 2018
Upgraded: Buy
Price Target: $52
Current: $12.34
Upside: n/a
Dec 7, 2017
Initiated Coverage: Buy
Price Target: $47
Current: $39.44
Upside: n/a